Explainer
Naltrexone Dosage: Label Doses for Alcohol, Opioids and Vivitrol, and What's Off-Label
Label doses for alcohol and opioid use disorder, the Vivitrol dose, missed doses, liver and kidney cautions, and which schedules are off-label.
By Naltrexone Reviews Editorial TeamUpdated 28 sourcesHow we check

On this page
Short answer
The label dose of naltrexone tablets is 50 mg once a day for alcohol or opioid use disorder; for opioids it starts at 25 mg.1 Vivitrol, the shot, is 380 mg every 4 weeks. Anyone who has used opioids must be opioid-free first, usually for at least 7 to 10 days.1,2 Your prescriber sets your dose.
Key takeaways
- 50 mg is the only strength of single-ingredient naltrexone tablet in the FDA's drug directory. Low-dose naltrexone (LDN) and the Sinclair method's dose timing are both off-label.1,3
- The label allows bigger doses on fewer days, such as 100 mg every other day, when someone supervises each dose. These may weaken the opioid block, and single doses above 50 mg may carry more liver risk.1
- The alcohol trials behind the label lasted up to 12 weeks. The VA/DoD guideline suggests considering stopping or switching if 3 months at 50 mg a day brings no benefit.1,4
- For a missed tablet, MedlinePlus says to take it when you remember unless the next dose is nearly due. A missed Vivitrol shot should be given as soon as possible.2,5
- Naltrexone does not cause dependence. For people who have used opioids, the danger after stopping is overdose, so talk to your prescriber before you stop.1,5
Naltrexone dosage at a glance
| Use | Form | Dose in the label or study | Status |
|---|---|---|---|
| Alcohol use disorder | Tablet | 50 mg once a day1 | FDA-approved |
| Opioid use disorder | Tablet | 25 mg on day 1, then 50 mg a day if there are no withdrawal signs1 | FDA-approved |
| Either, with each dose supervised | Tablet | 50 mg on weekdays and 100 mg on Saturday, 100 mg every other day, or 150 mg every third day1 | In the label |
| Alcohol or opioid use disorder | Vivitrol shot | 380 mg into the buttock muscle every 4 weeks or once a month2 | FDA-approved |
| Drinking, "targeted" (Sinclair method) | Tablet | 50 mg about 1 hour before drinking, only on drinking days6 | Off-label |
| Low-dose naltrexone (LDN) | No approved product | 4.5 mg or 6 mg a day in trials for Crohn's disease and fibromyalgia7,8 | Off-label |
| Weight loss | Contrave (with bupropion) | Up to 32 mg of naltrexone a day, as two 8 mg/90 mg tablets twice a day9 | FDA-approved (different product) |
Naltrexone doses by use and form, with whether each is in the FDA label.
Use: Alcohol use disorder
- Form
- Tablet
- Dose in the label or study
- 50 mg once a day1
- Status
- FDA-approved
Use: Opioid use disorder
- Form
- Tablet
- Dose in the label or study
- 25 mg on day 1, then 50 mg a day if there are no withdrawal signs1
- Status
- FDA-approved
Use: Either, with each dose supervised
- Form
- Tablet
- Dose in the label or study
- 50 mg on weekdays and 100 mg on Saturday, 100 mg every other day, or 150 mg every third day1
- Status
- In the label
Use: Alcohol or opioid use disorder
- Form
- Vivitrol shot
- Dose in the label or study
- 380 mg into the buttock muscle every 4 weeks or once a month2
- Status
- FDA-approved
Use: Drinking, "targeted" (Sinclair method)
- Form
- Tablet
- Dose in the label or study
- 50 mg about 1 hour before drinking, only on drinking days6
- Status
- Off-label
Use: Low-dose naltrexone (LDN)
- Form
- No approved product
- Status
- Off-label
Use: Weight loss
- Form
- Contrave (with bupropion)
- Dose in the label or study
- Up to 32 mg of naltrexone a day, as two 8 mg/90 mg tablets twice a day9
- Status
- FDA-approved (different product)
50 mg is the only tablet strength in the FDA's drug directory
Every single-ingredient naltrexone tablet in the FDA's National Drug Code directory is a 50 mg film-coated tablet. The other listings are bulk powder, extended-release injection kits, and Contrave.3 Drugs@FDA also shows 25 mg and 100 mg naltrexone tablets approved for one maker, but neither strength appears in the directory's current listings.10 The original brand, ReVia, is no longer sold, so the tablets you get are generic naltrexone hydrochloride.3,5
In clinical studies, one 50 mg tablet blocked the effects of 25 mg of injected heroin for up to 24 hours. Other data suggest that twice the dose blocks for 48 hours and three times the dose for about 72 hours.1 Those numbers are the basis for the supervised schedules below. How long the drug itself lasts is a separate question, covered in how long naltrexone stays in your system.
The 25 mg starting dose for opioid use disorder is half a tablet.11 The SpecGx tablet has a full score line across the middle.1 Other makers' tablets may differ, so ask your pharmacist whether yours can be split.
Alcohol use disorder: one 50 mg tablet a day
The tablet label and the VA/DoD guideline both give this dose for most people.1,4 The alcohol trials behind the label used it for up to 12 weeks, and "other dose regimens or durations of therapy were not evaluated" in them.1
Higher doses appear in research. COMBINE, a US trial of 1,383 people who had recently stopped drinking, gave 100 mg a day for 16 weeks and found naltrexone lowered the risk of a heavy drinking day.12 That is twice the label dose, and the label does not list it for alcohol. How naltrexone compared with acamprosate in that trial is on naltrexone vs acamprosate. How COMBINE fits with the other trials is shown on naltrexone success rates.
Starting on the shot. People should not be actively drinking at the first Vivitrol injection, and naltrexone does not ease alcohol withdrawal symptoms.2
Starting naltrexone: the first two weeks
- Before the first tablet. Tell your prescriber about any opioid use, including tramadol and opioid cough or diarrhea medicines. Opioids still in your body can set off sudden withdrawal. The usual gap is 7 to 10 days or more, and up to 2 weeks after buprenorphine or methadone.1
- Starting dose. To reduce nausea, the VA/DoD guideline lists 25 mg once or twice a day with meals, especially in the first week. UK guidance (NICE) starts at 25 mg, aiming for 50 mg.4,13
- Food and timing. VA/DoD advises taking each dose with food to ease stomach upset. MedlinePlus says to take it at about the same time each day.4,5
- Early side effects. Among about 570 people taking it for alcohol, 10% had new nausea and 7% a new headache.1 VA/DoD says side effects tend to come early and typically settle within 1 to 2 weeks after a dose change.4
- When to call. Call your prescriber if a side effect doesn't settle, and before you stop. Get help right away for vomiting, sweating or shaking after a dose, dark urine, yellow eyes, or new or worse depression. For suicidal thoughts, call or text 988.1,5,14
- Drinking on it. You can start while still drinking; VA/DoD recommends 2 to 4 alcohol-free days first for a better response.4,15 It causes no sickness reaction with alcohol.1 In lab studies, drinks felt less stimulating and more sedating, but people were just as impaired. Don't drive after drinking.16,17
For the wider picture of alcohol treatment, see naltrexone for alcohol use disorder.
Opioid use disorder: opioid-free first, then 25 mg
Naltrexone can set off sudden (precipitated) withdrawal in anyone who still has opioids in their body. That includes people taking it for alcohol who also use opioids.1 So both forms start after an opioid-free gap:
| Last opioid used | Tablet and Vivitrol labels | TIP 63 (SAMHSA's opioid-treatment guide) |
|---|---|---|
| Short-acting opioids, including tramadol and opioid-containing medicines | At least 7 to 10 days1,2 | 7 to 10 days11 |
| Buprenorphine or methadone | Withdrawal can still be set off for up to 2 weeks after stopping1 | 10 to 14 days for long-acting opioids11 |
How long to wait after the last opioid before the first naltrexone dose, from the labels and SAMHSA's TIP 63.
Last opioid used: Short-acting opioids, including tramadol and opioid-containing medicines
- TIP 63 (SAMHSA's opioid-treatment guide)
- 7 to 10 days11
Last opioid used: Buprenorphine or methadone
No test is completely reliable for showing someone has been off opioids long enough. A naloxone challenge (a small dose of naloxone given to check for withdrawal) can help. If it brings on withdrawal, the label says not to start yet and to repeat the challenge in 24 hours.1 What sudden withdrawal looks like is covered in naltrexone side effects.
The label then starts with 25 mg. If no withdrawal signs appear, the dose goes to 50 mg a day, which blocks injected opioids well enough.1 The smaller first dose may reduce nausea, and 50 mg can start on day 2.11
The tablet works for opioid use disorder "only when given as part of a comprehensive plan of management" that includes some way of making sure doses are taken.1 A SAMHSA prescriber advisory says research shows the monthly shot's "treatment outcomes are far superior to oral naltrexone, which makes it the preferred antagonist for treating OUD."18
Supervised schedules use bigger doses on fewer days
When someone watches each dose being taken, the tablet label allows three other patterns: 50 mg on weekdays with 100 mg on Saturday, 100 mg every other day, or 150 mg every third day.1
TIP 63 describes a three-day week adding up to 350 mg, such as 100 mg on Monday and Wednesday and 150 mg on Friday, which a spouse can observe.11
These schedules have two trade-offs. With longer gaps between doses, the opioid block may be weaker. And single doses above 50 mg may carry a higher risk of liver injury.1
Taking too much. In one study, people who took 800 mg a day for up to a week showed no signs of toxicity. Liver risk grows with dose over longer periods, though. At 300 mg a day in a placebo-controlled study, 19% (5 of 26) developed raised liver enzymes, against none on placebo.1
Vivitrol is one 380 mg dose every 4 weeks
Vivitrol is naltrexone in slow-release microspheres. A health care provider gives it as a deep injection into the buttock muscle every 4 weeks or once a month, switching sides each time.2 The 380 mg vial is the only strength sold.2
A 190 mg dose was tested in the main alcohol trial. It cut heavy drinking days by 17%, which missed statistical significance, while 380 mg cut them by 25%.19
Other label points on the shot2:
- No trial run on tablets is needed first.
- The opioid-free gap matches the tablet's.
- Switching from tablets to the shot has not been studied in a systematic way.
- One shot blocks opioids for about 28 days.
Amneal sells an unbranded Vivitrol kit under the same approval, with the same dosing.20 For more on the shot, see Vivitrol and naltrexone vs Vivitrol.
What to do after a missed dose
Tablets. The tablet label has no missed-dose instruction, and MedlinePlus says to take a missed dose when you remember.1 If it is almost time for the next one, skip the missed dose and carry on as usual. Don't take a double dose to make up.5
Vivitrol. If a shot is missed, the next one should be given as soon as possible.2 There are no data on restarting after a long gap, and the person must be opioid-free again first.2 TIP 63 says people treated for opioid use disorder can restart after 7 to 14 days without opioids.11
Why gaps matter with opioids. The opioid block fades after a missed tablet and toward the end of each month on the shot. Overdose risk is higher then. Both labels tell prescribers to make sure patients and caregivers know about overdose-reversal drugs such as naloxone and can get one.1,2 How the two drugs differ is explained on naltrexone vs naloxone.
Liver and kidney disease call for caution but few dose rules
The tablet label has no dose-adjustment table. The Vivitrol label is more specific, and the guidelines fill some gaps.
| Condition | Tablets (label) | Vivitrol (label) | Guidelines |
|---|---|---|---|
| Mild or moderate liver disease | No dose rule given. Exposure is about 5 times higher in compensated cirrhosis and 10 times higher in decompensated cirrhosis1 | No dose change for mild or moderate impairment (Child-Pugh A or B)2 | VA/DoD: use tablets with caution4 |
| Severe liver disease or acute hepatitis | Not adequately studied; stop if signs of acute hepatitis appear1 | Severe impairment not studied2 | APA: don't use in acute hepatitis or liver failure.21 VA/DoD: contraindicated4 |
| Mild kidney disease | Use with caution1 | No dose change (creatinine clearance 50 to 80 mL/min)2 | Not addressed |
| Moderate or severe kidney disease | Use with caution; not adequately studied1 | Not studied; use with caution2 | VA/DoD: caution with the shot below 50 mL/min.4 SAMHSA: caution in kidney failure18 |
Naltrexone dosing in liver and kidney disease, from the labels and guidelines.
Condition: Mild or moderate liver disease
Condition: Severe liver disease or acute hepatitis
Condition: Mild kidney disease
Condition: Moderate or severe kidney disease
Liver tests. Both guidelines check liver tests before starting and then from time to time: every 6 or 12 months in TIP 63, and at 6 and 12 months, then yearly, in VA/DoD.4,11 How other guidelines schedule liver tests, and the signs of liver injury, are on naltrexone liver tests.
Age. Safe use under 18 has not been established.1 Vivitrol's trials included few people over 65. Kidney function tends to drop with age, so its label says checking it may be useful in older adults.2
Targeted dosing (the Sinclair method) is off-label
The US label dose is daily.1 The Sinclair method uses the same 50 mg tablet another way. In Sinclair's Finnish protocol, people took it about 1 hour before drinking, and only on days they drank.6 Four targeted trials also used 50 mg, each with its own trigger:
- Daily for 12 weeks, then only when craving alcohol for 20 weeks (Finland, 121 people)22
- Before situations people judged high-risk for heavy drinking (two US trials, 153 and 163 people)23,24
- Targeted use in a 120-person US trial, where the median participant took it about 2.5 days a week25
What those trials found, and why the method's best-known success figure is not a trial result, is on our Sinclair method page. The opioid-free rule applies to targeted use too.1 Opioid-blocking drugs also do not block the loss of coordination that comes with drinking.6 For when to take a tablet around drinking, see drinking on naltrexone.
Low-dose naltrexone has no approved product
No low-dose naltrexone product is FDA-approved, so every LDN use in the US is off-label.3 LDN doses come from small trials. An adult Crohn's disease trial used 4.5 mg a day for 12 weeks. A fibromyalgia trial used 6 mg a day for 12 weeks and did not beat placebo on its main pain measure.7,8 Across naltrexone studies in general, doses have ranged from 3 mg to 250 mg.26 We found no primary source for an LDN titration schedule. The evidence by condition is on low-dose naltrexone. For medicine and surgery cautions at these off-label doses, far below the 50 mg tablet, see what to avoid on LDN.
For weight loss, the approved product is Contrave
Plain naltrexone is approved for alcohol dependence and for blocking opioids. Using it alone for weight loss is off-label.1 Contrave combines naltrexone with bupropion in 8 mg/90 mg extended-release tablets. Its label raises the dose each week until week 4, when it reaches two tablets twice a day (32 mg of naltrexone). The tablets should not be cut, chewed or crushed. Stopping is advised if weight has not dropped at least 5% after 12 weeks on the full dose. Contrave should not be taken with other naltrexone products.9 Separate naltrexone and bupropion tablets, and Contrave's safety rules, are covered on naltrexone and bupropion.
How long to take it, and stopping
How long. No label sets a maximum. When to expect a change, and when guidelines say to judge it, is on how long naltrexone takes to work.
- Alcohol, after a 12-week trial: in a 6-month follow-up, some benefits lasted after the pills stopped, but the effect on staying abstinent held only through the first month. Longer treatment may help some people.27
- A check-in point, not an end date: the VA/DoD guideline suggests considering stopping or switching to another option if 3 months on 50 mg a day brings no clear benefit.4
- Opioid use disorder: the best length of tablet treatment is unknown. People on the shot can stay on it as long as it helps and they want to continue. TIP 63's expert panel calls arbitrary time limits on the shot inappropriate.11
Stopping. Naltrexone does not cause physical or psychological dependence, and neither label gives a taper schedule.1,2 MedlinePlus advises against stopping without talking to your doctor first.5 After opioid use, tolerance is lower than before, so using opioids after stopping can lead to overdose.1 If you have surgery coming up, see stopping naltrexone before surgery.
Naltrexone needs a prescription but is not a controlled substance.1,28 See is naltrexone a controlled substance? To compare online prescribers and prices, see where to get naltrexone online and naltrexone cost.
Your experience: If you've taken naltrexone on a daily, targeted or monthly-shot schedule, you can share your story on our naltrexone reviews page.
Frequently asked questions
What is the naltrexone dose for alcohol?
The tablet label dose is 50 mg once a day. COMBINE, a US trial of 1,383 people, used 100 mg a day, which the label does not list for alcohol. See alcohol use disorder.1,12
Can you take 100 mg of naltrexone?
The label lists 100 mg doses only in supervised schedules, such as every other day. Single doses above 50 mg may raise the risk of liver injury. See supervised schedules.1
Should you take naltrexone in the morning or at night?
MedlinePlus says to take it at about the same time every day, with or without food. Whether morning or night suits you better depends on side effects; see morning or night.5
What if you miss a dose of naltrexone?
For tablets, MedlinePlus says to take it when you remember, unless the next dose is nearly due, and not to double up. A missed Vivitrol shot should be given as soon as possible. See missed doses.2,5
Is low-dose naltrexone the same as 50 mg naltrexone?
No. LDN uses much smaller doses, such as 4.5 mg, and no low-dose product is FDA-approved. See low-dose naltrexone.3,7
How we checked
- Doses come from the current tablet and Vivitrol labels (May 2026), SAMHSA's TIP 63 and alcohol advisory (2021), the VA/DoD 2021 dosing table, the APA 2018 guideline statements and NIAAA.1,2,4,11,15,18,21
- Tablet missed-dose and time-of-day advice comes from MedlinePlus, the National Library of Medicine's drug guide.5
- Every dose, blocking time and opioid-free gap was checked against the saved labels and TIP 63 on October 17, 2026; where TIP 63 says one tablet blocks for 72 hours, we used the label.
Related guides
References
28 sources, numbered in the order they are first cited (AMA style). Each is labelled by type so you can weigh it; commercial and media sources are never the only support for a clinical claim.
- 1.Naltrexone hydrochloride tablets USP, 50 mg. Prescribing information. SpecGx LLC; revised May 2026. DailyMed SPL version 15. Accessed October 17, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06ff2d5a-e62b-4fa4-bbdb-01938535bc65FDA drug label
- 2.Vivitrol (naltrexone for extended-release injectable suspension). Prescribing information. Alkermes, Inc.; revised May 2026. DailyMed SPL version 39. Accessed October 17, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd11c435-b0f0-4bb9-ae78-60f101f3703fFDA drug label
- 3.NDC directory: generic name naltrexone. openFDA. US Food and Drug Administration. Accessed October 17, 2026. https://api.fda.gov/drug/ndc.json?search=generic_name:naltrexone&limit=100Government source
- 4.US Department of Veterans Affairs; US Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. Version 5.0. 2021. Accessed October 17, 2026. https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/MH/sud/VA-DoD-SUD-CPG_Final_for-508_v3.pdfClinical guideline
- 5.Naltrexone. MedlinePlus. US National Library of Medicine. Updated September 15, 2026. Accessed October 17, 2026. https://medlineplus.gov/druginfo/meds/a685041.htmlGovernment source
- 6.Sinclair JD. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol. 2001;36(1):2-10. doi:10.1093/alcalc/36.1.2Narrative review · Narrative review written by the method's developer.
- 7.Parker CE, Nguyen TM, Segal D, MacDonald JK, Chande N. Low dose naltrexone for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2018;4(4):CD010410. doi:10.1002/14651858.CD010410.pub3Systematic review / meta-analysis · Our summary of this study
- 8.Due Bruun K, Christensen R, Amris K, et al. Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. 2024;6(1):e31-e39. doi:10.1016/S2665-9913(23)00278-3Randomized controlled trial · Our summary of this study
- 9.Contrave (naltrexone hydrochloride and bupropion hydrochloride) extended-release tablets. Prescribing information. Nalpropion Pharmaceuticals LLC; revised November 2025. DailyMed SPL version 27. Accessed October 17, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485ff360-32c8-11df-928b-0002a5d5c51bFDA drug label
- 10.Drugs@FDA: naltrexone (ANDA 076264, SpecGx LLC; and other naltrexone applications). openFDA, US Food and Drug Administration. Accessed October 17, 2026. https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:naltrexone&limit=100Government source
- 11.Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63. Publication No. PEP21-02-01-002. SAMHSA; 2021. Accessed October 17, 2026. https://library.samhsa.gov/sites/default/files/pep21-02-01-002.pdfClinical guideline
- 12.Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003-2017. doi:10.1001/jama.295.17.2003Randomized controlled trial · Our summary of this study
- 13.National Institute for Health and Care Excellence. Alcohol-Use Disorders: Diagnosis, Assessment and Management of Harmful Drinking (High-Risk Drinking) and Alcohol Dependence. Clinical guideline CG115. Published February 23, 2011. Updated October 21, 2014. Accessed October 17, 2026. https://www.nice.org.uk/guidance/cg115/chapter/RecommendationsClinical guideline
- 14.988 Suicide & Crisis Lifeline. Accessed October 17, 2026. https://988lifeline.org/Nonprofit organization
- 15.Recommend evidence-based treatment: know the options. In: Core Resource on Alcohol. National Institute on Alcohol Abuse and Alcoholism. Updated May 8, 2025. Accessed October 17, 2026. https://www.niaaa.nih.gov/health-professionals-communities/core-resource-on-alcohol/recommend-evidence-based-treatment-know-optionsGovernment source
- 16.Ray LA, Green R, Roche DJO, Magill M, Bujarski S. Naltrexone effects on subjective responses to alcohol in the human laboratory: a systematic review and meta-analysis. Addict Biol. 2019;24(6):1138-1152. doi:10.1111/adb.12747Systematic review / meta-analysis · Our summary of this study
- 17.McCaul ME, Wand GS, Eissenberg T, Rohde CA, Cheskin LJ. Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects. Neuropsychopharmacology. 2000;22(5):480-492. doi:10.1016/S0893-133X(99)00147-5Research study · Our summary of this study
- 18.Substance Abuse and Mental Health Services Administration. Prescribing Pharmacotherapies for Patients With Alcohol Use Disorder. Advisory. Publication No. PEP20-02-02-015. SAMHSA; 2021. Accessed October 17, 2026. https://library.samhsa.gov/sites/default/files/PEP20-02-02-015.pdfClinical guideline
- 19.Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617-1625. doi:10.1001/jama.293.13.1617Randomized controlled trial · Our summary of this study
- 20.Naltrexone for extended-release injectable suspension (kit). Prescribing information. Amneal Pharmaceuticals LLC; January 2026. DailyMed SPL version 1. Accessed October 17, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6de5637f-d527-4228-af1a-3aae71155cb5FDA drug label · Sold under Vivitrol's NDA 021897 without the brand name. We could not verify a price or current availability.
- 21.American Psychiatric Association. Guideline statement summary. In: The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. American Psychiatric Association Publishing; 2018. Accessed October 17, 2026. doi:10.1176/appi.books.9781615371969Clinical guideline
- 22.Heinälä P, Alho H, Kiianmaa K, Lönnqvist J, Kuoppasalmi K, Sinclair JD. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2001;21(3):287-292. doi:10.1097/00004714-200106000-00006Randomized controlled trial · Our summary of this study
- 23.Kranzler HR, Armeli S, Tennen H, et al. Targeted naltrexone for early problem drinkers. J Clin Psychopharmacol. 2003;23(3):294-304. doi:10.1097/01.jcp.0000084030.22282.6dRandomized controlled trial · Our summary of this study
- 24.Kranzler HR, Tennen H, Armeli S, et al. Targeted naltrexone for problem drinkers. J Clin Psychopharmacol. 2009;29(4):350-357. doi:10.1097/JCP.0b013e3181ac5213Randomized controlled trial · Our summary of this study
- 25.Santos GM, Ikeda J, Coffin P, et al. Targeted oral naltrexone for mild to moderate alcohol use disorder among sexual and gender minority men: a randomized trial. Am J Psychiatry. 2022;179(12):915-926. doi:10.1176/appi.ajp.20220335Randomized controlled trial · Our summary of this study
- 26.Bolton M, Hodkinson A, Boda S, et al. Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis. BMC Med. 2019;17(1):10. doi:10.1186/s12916-018-1242-0Systematic review / meta-analysis · Our summary of this study
- 27.O'Malley SS, Jaffe AJ, Chang G, et al. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry. 1996;53(3):217-224. doi:10.1001/archpsyc.1996.01830030039007Research study · Our summary of this study
- 28.Schedule II, 21 CFR §1308.12 (2026). eCFR version as of October 1, 2026. Accessed October 17, 2026. https://www.ecfr.gov/current/title-21/chapter-II/part-1308/section-1308.12Government source
Medical disclaimer
This page is for general information only and is not medical advice. It does not replace advice from your own clinician or pharmacist. Don't start, stop or change a medicine or dose without talking to your prescriber. If you are physically dependent on alcohol, stopping suddenly can be dangerous; get medical advice first. If you use opioids, starting naltrexone in either form can cause sudden, severe withdrawal.
Full medical disclaimer.